SFDA withdraws “Jusprin 81 mg” from market due to quality flaws

The Saudi Food and Drug Authority (SFDA) has pulled back the prescription "Jusprin 81 mg" from the market because of value imperfections, Saudi Press Agency (SPA) said. 

The SFDA has likewise kept in touch with wellbeing specialists to quit utilizing the drug. 

This measure has come after the SFDA gotten data from Julphar, the assembling organization, that all clumps and types of Jusprin 81 mg have quality defects. Thus, the Authority has constrained Julphar to pull back all clumps and types of the prescription from all offices administering the medication. It approached those utilizing the prescription to see their specialists. 

For the individuals who require more data, the SFDA has approached people in general to call the Unified Call Center number 19999 at the SFDA.